Burkitt Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
DZ-CIS downregulated c-myc and overcame CIS resistance in myc-driven TP53-mutated aggressive B cell Burkitt lymphoma.
|
30840322 |
2019 |
Burkitt Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: Targeting MDM4 to alleviate degradation of p53 can be exploited therapeutically across Burkitt lymphoma and other cancers with wild-type p53 harboring 1q gain, the most frequent copy number alteration in cancer.
|
31000522 |
2019 |
Burkitt Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Additionally, PTEN negatively correlated with p53 expression in FL and CGB DLBCL, whereas NF-κB negatively correlated with WWP2 in GCB DLBCL, but positively associated with PTEN in RFH and c-Myc in BL.
|
30899409 |
2019 |
Burkitt Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To discover regulators of mutp53 protein accumulation, we performed a large-scale RNA interference screen in a Burkitt lymphoma cell line model.
|
29653964 |
2018 |
Burkitt Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We verified that the oncogenic effect of iASPP on Burkitt lymphoma is TAp63 dependent rather than p53 and confirmed that the interaction between CDK1 and iASPP enhanced the inhibitory effect of iASPP on p53 and TAp63.
|
30105797 |
2018 |
Burkitt Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Combined loss of p53 induction and function due to miRNA-mediated regulation of ATM and NLK, together with the upregulation of TFAP4, may be a central role for human miRNAs in eBL oncogenesis.
|
29132323 |
2017 |
Burkitt Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
INZ(c) treatment decreased c-Myc expression at both mRNA and protein level, and suppressed c-Myc transcriptional activity in human Burkitt's lymphoma Raji cells with mutant p53.
|
25692307 |
2015 |
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We identified TP53 mutations in MYC+/BCL2+ lymphomas at a frequency intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.
|
24679006 |
2015 |
Burkitt Lymphoma
|
0.400 |
SusceptibilityMutation
|
disease |
ORPHANET |
Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing.
|
23255406 |
2013 |
Burkitt Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated TP53 pathway disruption in paediatric BL patient samples (n = 30) by studying MDM4, MDM2, and CDKN1A (p21) protein and mRNA expression; TP53 mutations; TP53 protein expression; and gene copy number abnormalities.
|
22845047 |
2012 |
Burkitt Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In order to better understand the mechanisms by which chemoresistance is mediated, non-hodgkin's lymphoma (NHL) patients overexpressing p53 mutant protein and resistant to CHOP chemotherapy, NHL patients without p53 overexpression and a Burkitt's lymphoma Raji cell line with p53 overexpression have been evaluated using fluorescent in situ hybridization (FISH) and comparative genomic hybridization (CGH).
|
21888455 |
2011 |
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutation of the p53 tumor suppressor is associated with disease progression, therapeutic resistance, and poor prognosis in patients with lymphoid malignancies and can occur in approximately 50% of Burkitt lymphomas.
|
20179179 |
2010 |
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results showed that BL cell lines have variable response to DNA-damaging agents that cannot be correlated exclusively with p53 mutation or survivin expression suggesting that p53-independent transactivation may play a role in apoptosis induced by DNA-damaging agents.
|
19557576 |
2009 |
Burkitt Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This work shows that LMP2A can permit tumorigenesis in the presence of an intact p53 pathway, identifying an important contribution of EBV to BL.
|
19815507 |
2009 |
Burkitt Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we show that chloroquine, a drug that activates the stress-responsive Atm-p53 tumor-suppressor pathway, preferentially enhances the death of Myc oncogene-overexpressing primary mouse B cells and mouse embryonic fibroblasts (MEFs) and impairs Myc-induced lymphomagenesis in a transgenic mouse model of human Burkitt lymphoma.
|
18097482 |
2008 |
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We used these methods to characterize the p53 mutation in tumor cells of a 53-year-old male suffering from Burkitt's lymphoma.
|
18813817 |
2008 |
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
We used these methods to characterize the p53 mutation in tumor cells of a 53-year-old male suffering from Burkitt's lymphoma.
|
18813817 |
2008 |
Burkitt Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Similarly, human Burkitt lymphomas with wild-type p53 and overexpression of Hdm2 are highly sensitive to proteasome inhibitors, unless p53 levels are reduced using the HPV-E6 ubiquitin ligase.
|
17284530 |
2007 |
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Direct sequencing revealed a point mutation in the p53 gene in four BL.
|
14712292 |
2004 |
Burkitt Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of endogenous wt p53 in BLs and lymphoblastoid cell lines led to the induction of SAP and this was inhibited by the specific p53 inhibitor pifithrin-alpha.
|
15378026 |
2004 |
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations of TP53 were detected in 11 of 49 (22.5%) patients and more specifically in 20% of Burkitt's lymphoma.
|
12890146 |
2003 |
Burkitt Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This indicates that disruption of both the pRb and p53 tumor suppressor pathways is critical for BL development.
|
12191637 |
2002 |
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes.
|
11482875 |
2002 |
Burkitt Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The molecular biological characteristics of Burkitt lymphoma (BL), in addition to the presence of the Epstein-Barr virus (EBV) in some forms, relies on well-characterized alterations, such as MYC translocations and TP53 inactivations.
|
11793449 |
2002 |
Burkitt Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical overexpression of p53 protein was found in 21% of NHL patients, with the highest incidence of p53 immunoreactivity in cases of Burkitt's lymphoma, follicle center lymphoma grade III, and diffuse large B-cell lymphoma.
|
12044054 |
2002 |